Biogen brags of Phase III data for would-be Aubagio rival oral MS drug
Thursday's news brings the drug one step closer to its built-in fan base. It also comes a week after the FDA approved Sanofi's oral contender, Aubagio (teriflunomide). Phase III trials of Sanofi's therapy reduced the relapse rate among MS patients by about 30%. Industry watchers told MM&M at the time that the approval expanded patient options, but it was going to have a longer acceptance curve among physicians than BG-12, which has cultivated a level of pre-approval confidence with its safety and efficacy profile.
Ben Weintraub, director of research at the health analytics firm InThought, told MM&M at the time of Sanofi's Augbagio approval that this will translate into doctor preference for the Biogen Idec drug over rivals like Aubagio or Tysabri for second-line use when interferon and Copaxone fail.